- Home
- EDN vs XNCR Comparison
EDN vs XNCR Comparison
Compare EDN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDN | XNCR |
|---|---|---|
| Founded | 1992 | 1997 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2007 | 2013 |
Fundamental Metrics
Financial Performance| Metric | EDN | XNCR |
|---|---|---|
| Price | $24.26 | $20.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $22.33 |
| AVG Volume (30 Days) | 46.4K | ★ 1.0M |
| Earning Date | 03-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $13.19 | N/A |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $14.38 | $6.92 |
| 52 Week High | $36.70 | $21.96 |
Technical Indicators
Market Signals| Indicator | EDN | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 62.52 |
| Support Level | $24.41 | $11.20 |
| Resistance Level | $29.64 | $21.26 |
| Average True Range (ATR) | 1.32 | 1.55 |
| MACD | -0.07 | -0.10 |
| Stochastic Oscillator | 14.58 | 55.05 |
Price Performance
Historical ComparisonAbout EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires, mainly for residential, commercial, industrial, and public service.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.